Quantitative proteome profiling to identify biomarkers and therapeutic targets for adult T-cell leukemia (ATL).
Project/Area Number |
23701090
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor diagnosis
|
Research Institution | The Institute of Physical and Chemical Research |
Principal Investigator |
ISHIHARA Makoto 独立行政法人理化学研究所, バイオマーカー探索・開発チーム, 特別研究員 (60581189)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | プロテオミクス / 質量分析 / ATL / HTLV-1 / 機械学習 / 診断マーカー / 治療標的 / プロテオミクス解析 |
Research Abstract |
ATL is one of the most aggressive hematologic malignancies caused by human T-lymphotropic virus type 1 (HTLV-1) infection. The prognosis of ATL is extremely poor; however, effective strategies for diagnosis and treatment have not been established. 2-step statistical analysis for 14,064 peptides detected through focused proteomic profiling of the HTLV-1 enriched CD4^+CD25^+CCR4^+ T-cell subpopulation on 29 clinical cases were performed. 91 peptide determinants that statistically classified 4 clinical groups with an accuracy rate of 92.2% by cross-validation test were extracted, resulting in the identification of 17 classifier proteins which were potential diagnostic biomarkers and an attractive resource of therapeutic targets for ATL.
|
Report
(3 results)
Research Products
(13 results)
-
-
-
[Journal Article] Plasmin inhibitor reduces lymphoid tumor growth by suppressing matrixmetallproteinase-9 dependent CD11b+/F4/80+ myeloid cell recruitment2012
Author(s)
Ishihara M, Heissig B, Nishida C, Rosenkvist J, Tashiro Y, Ohki M, Wanaka K, Tsuda Y, Okada Y, Nakauchi H, Hattori K
-
Journal Title
Leukemia
Volume: 26
Issue: 2
Pages: 332-339
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-